Pfizer’s maternal vaccine against the respiratory syncytial virus reduced the rate of severe illness in newborns by 81.8%, the company said Tuesday, meeting the goal of a pivotal study.
The company said that it plans to file the data on the vaccine with regulators by the end of the year and that it expects an eight-month review.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
